Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Leuk Lymphoma. 2020 Dec;61(12):2790-2798. doi: 10.1080/10428194.2020.1788017. Epub 2020 Jul 9.
The emergence of the Coronavirus Disease -19 (COVID-19) pandemic, has had a tremendous global impact, resulting in substantial morbidity and mortality worldwide and especially in the United States, where nearly one third of the cases are located. Although involvement of the lower respiratory track accounts for most of the morbidity and mortality seen, the virus involves several organ systems and the syndrome exhibits clinical diversity with a wide range of symptoms and manifestations. The involvement of elements of the hematopoietic system is prominent in severe cases and associated with poor outcomes and mortality. Lymphopenia, leukopenia, thrombocytopenia, disseminated intravascular coagulation, and a prothrombotic state are common manifestations of COVID-19 and have important treatment and prognostic implications. Better understanding of the mechanisms of the pathophysiology of COVID-19-induced hematological abnormalities may ultimately result in better ways to treat them and decrease the associated morbidity and mortality.
新型冠状病毒病(COVID-19)大流行的出现对全球产生了巨大影响,导致全球发病率和死亡率大幅上升,尤其是在美国,美国的病例几乎占了三分之一。虽然下呼吸道受累是导致大部分发病率和死亡率的原因,但该病毒涉及多个器官系统,且该综合征的临床表现具有多样性,症状和表现范围广泛。造血系统的受累在重症病例中很突出,与不良结局和死亡率相关。淋巴细胞减少症、白细胞减少症、血小板减少症、弥散性血管内凝血和血栓前状态是 COVID-19 的常见表现,对治疗和预后有重要影响。更好地了解 COVID-19 引起的血液学异常的病理生理学机制,最终可能会找到更好的治疗方法,并降低相关的发病率和死亡率。